Cybin Inc. (CYBN)
8.83
-0.07 (-0.79%)
At close: Jan 14, 2025, 3:59 PM
Company Description
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics.
The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation.
It has also developed EMBARK, a psychedelic-assisted psychotherapy.
The company is headquartered in Toronto, Canada.
Cybin Inc.
| Country | CA |
| IPO Date | Sep 13, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 50 |
| CEO | Douglas L. Drysdale |
Contact Details
Address: 100 King Street West Toronto, ON CA | |
| Website | https://www.cybin.com |
Stock Details
| Ticker Symbol | CYBN |
| Exchange | AMEX |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001833141 |
| CUSIP Number | 23256X100 |
| ISIN Number | CA23256X1006 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Douglas L. Drysdale | Chief Executive Officer |
| Aaron Bartlone | Chief Operating Officer |
| Gabriel Fahel | Chief Legal Officer & Corporate Secretary |
| Greg Cavers | Chief Financial Officer |
| Dr. Alex L. Nivorozhkin Ph.D. | Chief Scientific Officer |
| Eric So L.L.B. | Co-Founder, President & Executive Chairman |
| George Tziras | Chief Business Officer & Director |
| John Kanakis | Co-Founder |
| Lori Challenger | Chief Compliance, Ethics & Administrative Officer |
| Paul Glavine | Co-Founder, Chief Growth Officer & Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 13, 2025 | 6-K | Filing |
| Jan 10, 2025 | 6-K | Filing |
| Jan 08, 2025 | F-X | Filing |
| Jan 08, 2025 | F-10 | Filing |
| Dec 10, 2024 | 6-K | Filing |
| Dec 10, 2024 | D | Filing |
| Dec 04, 2024 | 6-K | Filing |
| Dec 03, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 18, 2024 | 6-K | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |